Stock GILD34 GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 11:21:12 10/05/2024 pm IST 		5-day change 1st Jan Change
169.9 BRL -1.92% Intraday chart for Gilead Sciences, Inc. +3.77% -11.73%
07/05 Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
02/05 UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees: 18,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
27,281 100.0 % 27,116 100.0 % -0.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
71.7 %
18,884 69.2 % 19,438 71.7 % +2.93%
Europe
15.9 %
4,469 16.4 % 4,310 15.9 % -3.56%
Other International
12.4 %
3,928 14.4 % 3,368 12.4 % -14.26%

Managers

Managers TitleAgeSince
Daniel O'Day CEO
 Chief Executive Officer 59 01/19/01
Andrew Dickinson DFI
 Director of Finance/CFO 54 01/16/01
Flavius Martin CTO
 Chief Tech/Sci/R&D Officer - 12/21/12
Merdad Parsey CTO
 Chief Tech/Sci/R&D Officer 61 01/19/01
Jacquie Ross IRC
 Investor Relations Contact - 01/21/01
Adam Levy PRN
 Corporate Officer/Principal - -
Stacey Ma PRN
 Corporate Officer/Principal 54 18/22/18
Tomas Cihlar PRN
 Corporate Officer/Principal 57 -
Jyoti Mehra HRO
 Human Resources Officer 48 01/17/01
Joydeep Ganguly PRN
 Corporate Officer/Principal - 01/19/01

Members of the board

Members of the board TitleAgeSince
Anthony Welters BRD
 Director/Board Member 69 17/20/17
Jacqueline Barton BRD
 Director/Board Member 71 01/18/01
Ted Love BRD
 Director/Board Member 65 01/02
Harish M. Manwani BRD
 Director/Board Member 70 09/18/09
Javier Rodriguez BRD
 Director/Board Member 53 15/20/15
Daniel O'Day CEO
 Chief Executive Officer 59 01/19/01
Sandra Horning BRD
 Director/Board Member 75 28/20/28
Kelly Kramer BRD
 Director/Board Member 56 19/16/19
Jeffrey Bluestone BRD
 Director/Board Member 70 07/20/07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,245,853,209 1,244,654,868 ( 99.90 %) 0 99.90 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
8.976 %
111,822,428 8.976 % 8 191 M R$
BlackRock Advisors LLC
7.472 %
93,089,266 7.472 % 6 819 M R$
Capital Research & Management Co. (World Investors)
6.692 %
83,364,123 6.692 % 6 106 M R$
Capital Research & Management Co. (Global Investors)
4.789 %
59,657,126 4.789 % 4 370 M R$
STATE STREET CORPORATION
4.779 %
59,536,425 4.779 % 4 361 M R$
Dodge & Cox
2.673 %
33,295,023 2.673 % 2 439 M R$
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.205 %
27,471,926 2.205 % 2 012 M R$
Geode Capital Management LLC
2.029 %
25,274,185 2.029 % 1 851 M R$
Wellington Management Co. LLP
1.495 %
18,630,134 1.495 % 1 365 M R$
Eaton Vance Management
1.429 %
17,801,718 1.429 % 1 304 M R$
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000361 %
8,986 0.000361 % 325 274 R$
Bram Bradesco Asset Management S/A DTVM
0.000221 %
5,500 0.000221 % 199 088 R$
Western Asset Management Company DTVM Ltda.
0.000002 %
59 0.000002 % 2 136 R$

Holdings

NameEquities%Valuation
ARCUS BIOSCIENCES, INC.
34.70%
 31,532,781 34.70% 595,338,905 $
GALAPAGOS NV
25.35%
 16,707,477 25.35% 533,743,743 $
ARCELLX, INC.
12.73%
 6,720,803 12.73% 467,431,849 $
KYVERNA THERAPEUTICS, INC.
9.57%
 4,126,119 9.57% 102,492,796 $
TANGO THERAPEUTICS, INC.
4.55%
 4,854,443 4.55% 38,544,277 $
ASSEMBLY BIOSCIENCES, INC.
19.87%
 1,089,468 19.87% 14,489,924 $
LEAP THERAPEUTICS, INC.
20.78%
 5,319,148 20.78% 14,148,934 $
HOOKIPA PHARMA INC.
23.00%
 18,759,465 23.00% 13,356,739 $
ALLOVIR, INC.
14.58%
 16,635,286 14.58% 12,559,641 $
XILIO THERAPEUTICS, INC.
26.67%
 7,345,473 26.67% 7,933,111 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD34)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
Gilead Therapeutics A1 Unlimited Co.
Logo Gilead Therapeutics A1 Unlimited Co.

Gilead Therapeutics A1 Unlimited Co.

Pharmaceuticals: MajorHealth Technology

Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The private company is located in Ireland.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96 USD
Average target price
82.93 USD
Spread / Average Target
+25.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD34 Stock
  5. Company Gilead Sciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW